A study performed at Dana-Farber/Children's Hospital Cancer Center in Boston has found that nearly two-thirds of children receiving stem cell transplants returned to the hospital within six months for treatment due to unexplained fevers, infections or other problems.
Children who received donor cells were twice as likely to be readmitted as children who received their own stem cells.
Advertisement
"No one had ever looked at these data in children," said Leslie E. Lehmann, MD, clinical director of pediatric stem cell transplantation at Dana-Farber/Children's Hospital Cancer Center (DF/CHCC). "This is very important information and will allow us to counsel families appropriately, as well as try to devise interventions that reduce the rate of readmissions."
The study by Lehmann and Harvard Medical School student David Shulman is being presented at the 26th annual meeting of the American Society of Pediatric Hematology Oncology in Miami, April 24-27.
![Stem Cells - Cord Blood]( "Stem Cells - Cord Blood")
A record review of 129 children from 2008 to 2011 revealed that 64 percent had at least one hospital readmission within 180 days of transplant. The source of the donor cells was a key predictor: 79 percent of patients receiving transplants from a related or unrelated donor were readmitted compared to 38 percent who received their own cells (autologous transplant). The mean number of readmissions was 2.4, indicating that for some children, discharge after transplant is just the beginning of a long process characterized by repeated hospital stays. Fever without a documented source of infection accounted for 39 percent of the readmissions; 24 percent were for infections and 15 percent for gastrointestinal problems.
"Most of the patients went on to be successfully treated and ultimately did very well," commented Lehmann.
"We hope these findings can eventually lead to identifying a group of low-risk children who could be managed at local hospitals rather than transplant centers, reducing costs and inconvenience to families."
Lehmann said the goal is to identify which patients could be safely treated without requiring an admission to the hospital.
Source: Eurekalert
Advertisement
A record review of 129 children from 2008 to 2011 revealed that 64 percent had at least one hospital readmission within 180 days of transplant. The source of the donor cells was a key predictor: 79 percent of patients receiving transplants from a related or unrelated donor were readmitted compared to 38 percent who received their own cells (autologous transplant). The mean number of readmissions was 2.4, indicating that for some children, discharge after transplant is just the beginning of a long process characterized by repeated hospital stays. Fever without a documented source of infection accounted for 39 percent of the readmissions; 24 percent were for infections and 15 percent for gastrointestinal problems.
"Most of the patients went on to be successfully treated and ultimately did very well," commented Lehmann.
"We hope these findings can eventually lead to identifying a group of low-risk children who could be managed at local hospitals rather than transplant centers, reducing costs and inconvenience to families."
Lehmann said the goal is to identify which patients could be safely treated without requiring an admission to the hospital.
Source: Eurekalert
Bone Marrow Aspiration and Biopsy
Bone marrow biopsy and aspiration is the removal of some bone marrow tissue for diagnosis and management of cancers of blood cells and multiple myeloma.
Advertisement
Advertisement
|
Advertisement
Recommended Readings
Latest Genetics & Stem Cells News
Among MS patients, the stem cells showed a neuroprotective role, guarding nerve cells from further decline.
New possibilities for research on digestive diseases have been set by complete decoding of the Y chromosome.
UK has given the green light to the world's inaugural gene therapy for sickle-cell disease and thalassemia.
1 in 25 people had a genotype linked to short lifetime, which includes BRCA2 and LDLR genes, that reduced lifespan by seven years, and six years respectively.
The study findings help redefine osteoarthritis as a reversible loss of key cartilage stem cells, not just 'wear and tear'."